Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Two-Drug attack on deadly melanoma in the brain

NCT ID NCT03873818

Summary

This study tested a combination of two immunotherapy drugs, ipilimumab and pembrolizumab, in patients whose melanoma had spread to their brain. The goal was to see if using a lower dose of ipilimumab with pembrolizumab was safe and could help control the cancer in the brain. The trial included 24 patients who had not yet received certain other immunotherapies for their advanced cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.